Status: Finalised
First registered on:
21/04/2016
Last updated on:
16/01/2017
1. Study identification
EU PAS Register NumberEUPAS13238
Official titleReal-life effectiveness evaluation of budesonide/formoterol (BF) Spiromax for the management of asthma and COPD
Study title acronym
Study typeObservational study
Brief description of the studyFour complimentary post-marketing retrospective observational studies to evaluate the real-life effectiveness and cost-effectiveness of BF Spiromax and to characterise patients prescribed BF Spiromax in the two years following product launch in the United Kingdom
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupResearch in Real Life Ltd
Organisation/affiliationOPRI Pte Ltd
Details of (Primary) lead investigator
Title Dr
Last name Voorham
First name Jaco
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed20/03/201520/03/2015
Start date of data collection16/09/201516/09/2015
Start date of data analysis09/05/2016
Date of interim report, if expected29/01/201629/01/2016
Date of final study report03/02/201716/01/2017
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesTeva Pharmaceutical Industries100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
Postcode
CountryUnited Kingdom
Phone number (incl. country code)44-1223967582
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
Postcode
CountryUnited Kingdom
Phone number (incl. country code)44-1223967582
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameSpiromax
CountryUnited Kingdom
Substance INN(s)BUDESONIDE
FORMOTEROL FUMARATE DIHYDRATE
Product NameSymbicort Turbohaler
CountryUnited Kingdom
Substance INN(s)BUDESONIDE
FORMOTEROL FUMARATE DIHYDRATE
Product NameSeretide Accuhaler
CountryUnited Kingdom
Substance INN(s)FLUTICASONE PROPIONATE
SALMETEROL XINAFOATE
7. Medical conditions to be studied
Medical condition(s)Yes
Asthma
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects6400
Additional information
Approx. 400 patients prescribed Spiromax.
Approx. 3000 patients prescribed Symbicort Turbohaler.
Approx. 3000 patients prescribed Seretide Accuhaler
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Effectiveness evaluation
Primary scope : Effectiveness evaluation
12. Main objective(s)
What is the main objective of the study?
To characterise patients who change to BF Spiromax from another FDC ICS/LABA and evaluate acceptability, and the real-life effectiveness and cost-effectiveness of BF Spiromax.
Are there primary outcomes?Yes
Risk Domain Control (binary)
Are there secondary outcomes?Yes
Comparison of severe exacerbation rate; treatment stability; SABA usage; and lower respiratory-related hospitalisations.
Cost-effectiveness in relation to asthma- and COPD-related total and disaggregated respiratory therapy prescription costs; primary care consultation costs; and respiratory-related hospitalisation costs.
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Statistically significant results will be defined as p<0.05 and trends as 0.05<p<0.10. Summary statistics will be produced for all baseline and outcome variables, for each study phase cohort. In phase 4, patients will be uniquely matched on demographics and key measures of disease severity to minimise confounding. Matching variables will be selected based on clinical review and baseline differences between the treatment groups. Matching will be conducted separate for asthma and COPD patients. The primary outcome will be analysed using conditional logistic regression, separately for asthma and COPD patients. Secondary outcomes will be analysed using conditional poisson, logistic, and ordinal logistic regression as appropriate, separately for asthma and COPD patients.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
